[Ip-health] 6 Senators, 6 Representatives Send Letter to NIH in Support of Xtandi March-in

Ruth Lopert ruth.lopert at gmail.com
Thu Mar 31 06:14:35 PDT 2016

I was thinking the same thing myself. I'm wondering though, is there
anything in Bayh-Dole that could be used to require UCLA to return some of
NIH's research $ out of the $1.14 billion it sold the royalties for?

Ruth Lopert

On Thu, Mar 31, 2016 at 7:59 PM, Shadlen,K <K.Shadlen at lse.ac.uk> wrote:

> Given that a firm purchased the rights to future royalties from UCLA for
> $1.14 billion, buyer must be pretty confident this request will be ignored
> (or someone at royalty pharma will be out of a job soon).
> http://www.royaltypharma.com/images/royalty/PressReleases/Royalty_Pharma_UCLA_joint_Press_Release_Acquisition_of_Xtandi_Royalty_March_4_2016.pdf
> Ken
> -----Original Message-----
> From: Ip-health [mailto:ip-health-bounces at lists.keionline.org] On Behalf
> Of Zack Struver
> Sent: 28 March 2016 22:08
> To: ip-health at lists.keionline.org
> Subject: [Ip-health] 6 Senators, 6 Representatives Send Letter to NIH in
> Support of Xtandi March-in
> Press Release:
> http://www.sanders.senate.gov/newsroom/press-releases/lawmakers-to-nih-and-hhs-act-now-on-drug-affordability
> ​Letter:
> http://www.sanders.senate.gov/download/congressional-letter-to-nih-and-hhs-regarding-xtandi?inline=file
> Lawmakers to NIH and HHS: Act Now on Drug Affordability
> Monday, March 28, 2016
> WASHINGTON, March 28 - A group of Senate and House lawmakers led by Reps.
> Lloyd Doggett (D-Texas) and Peter Welch (D-Vt.), co-chairs of the
> Prescription Drug Taskforce, as well as Sen. Bernie Sanders (I-Vt.), today
> urged the Department of Health and Human Services and the National
> Institutes of Health to step in to lower the cost of a prostate cancer
> drug, Xtandi, which costs four times more in the United States than in
> other major countries.
> “When Americans pay for research that results in a safe and effective
> drug, an unreasonably high cost should not limit their access to it. New
> treatments are meaningless if patients cannot afford them,” the lawmakers
> wrote in a letter to HHS Secretary Sylvia Burwell and NIH Director Francis
> Collins.
> In the letter, the members called on NIH to hold a public hearing to
> consider overriding the patent on Xtandi to make the drug available at a
> lower price. Under current law, NIH can take this step if federal funds
> supported a drug’s development and the company is selling it at an
> unreasonably high price.
> Xtandi was developed at the University of California, Los Angeles, through
> taxpayer-supported research grants from the U.S. Army and NIH. The
> medication, which is sold by Japanese drugmaker Astellas Pharma, has an
> average wholesale price in the U.S. of more than $129,000. It is sold in
> Japan and Sweden for $39,000 and in Canada for $30,000.
> “We do not think that charging U.S. residents more than anyone else in the
> world meets the obligation to make the invention available to U.S.
> residents on reasonable terms,” the members wrote.
> Sanders, Doggett and Welch were joined by Sens. Al Franken (D-Minn.),
> Sheldon Whitehouse (D-R.I.), Amy Klobuchar (D-Minn.), Patrick Leahy (D-Vt.)
> and Elizabeth Warren (D-Mass.), as well as Reps. Elijah Cummings (D-Md.),
> Jan Schakowsky (D-Ill.), Rosa DeLauro (D-Conn.) and Mark Pocan (D-Wis.).
> “When Americans pay for research that results in a pharmaceutical, that
> drug should be available at a reasonable price,” said Doggett, ranking
> member of the Subcommittee on Human Resources of the House Ways and Means
> Committee and co-chair of the House Democratic Caucus Prescription Drug
> Task Force. “The Administration has said it is prepared to use its existing
> authority to address this problem on a case-by-case basis; it should do so
> now with Xtandi. An unaffordable drug is 100 percent ineffective. Americans
> shouldn’t have to choose between their lives and their livelihoods on this
> and many other outrageously priced medications.”
> “The United States government should use every tool available to lower
> outrageously high prescription drug prices,”Sanders said. “NIH has the
> power to stop this blatant profiteering and put the pharmaceutical industry
> on notice that the era of charging unconscionable prices must end.”
> “Pharmaceutical companies provide good drugs that are life-saving and
> pain-relieving, but their prices are killing us,” Welch said. “Taxpayers
> foot a hefty bill so companies like Astellas Pharma can conduct research
> and improve their drugs.  And yet they charged substantially higher prices
> than patients in other countries for they very drugs produced by that
> research. The NIH has the authority to step in to end this price gouging
> and should do so as soon as possible.”
> “The rising costs of prescription drugs have left families throughout
> Minnesota and the entire country with the impossible choice of either
> buying their medications or paying their bills,” said Franken, a member of
> the Senate Health Committee. “Drug prices are out of control, and I believe
> we need a comprehensive plan to address this growing problem. One step we
> can take is to have the Obama Administration crack down on price gouging
> and use its authority to ensure access to important medications.”
> To read the letter, click
> ​here
> <
> http://www.sanders.senate.gov/download/congressional-letter-to-nih-and-hhs-regarding-xtandi?inline=file
> >
>> .
> --
> Zack Struver, Communications and Research Associate Knowledge Ecology
> International zack.struver at keionline.org
> Twitter: @zstruver <https://twitter.com/zstruver>
> Office: +1 (202) 332-2670 Cell: +1 (914) 582-1428 keionline.org
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org

More information about the Ip-health mailing list